EMT interrupted

Oncodrone B.V. is developing a small molecule that can disrupt the epithelial-mesenchymal transition to prevent tumor cells from gaining invasive and malignant properties. The biotech plans to develop the compound for aggressive tumors such as pancreatic or stomach cancers, but first it needs to home in on the molecule's target.

The epithelial-mesenchymal transition (EMT) allows cancer cells to metastasize by causing a gradual loss of original cellular characteristics. ...